Sanofi (SNYNF) SEC Filings — 2025
50 SEC filings for Sanofi (SNYNF) in 2025.
Filings
- Sanofi Updates Tolebrutinib Regulatory Submission — 6-K · Dec 29, 2025
- Sanofi 6-K Filing — 6-K · Dec 23, 2025
- Sanofi Agrees to Lower Drug Costs with US Government — 6-K · Dec 22, 2025
- Sanofi 6-K Filing — 6-K · Dec 15, 2025
- Sanofi 6-K Filing — 6-K · Dec 12, 2025
- Sanofi's Dupixent Gets EU Approval as First Targeted Medicine — 6-K · Dec 3, 2025
- Sanofi's Dupixent Study Meets Endpoints — 6-K · Nov 18, 2025
- Sanofi 13F-HR Filing — 13F-HR · Nov 4, 2025
- Sanofi 6-K Filing — 6-K · Nov 3, 2025
- Sanofi's efdoralprin alfa shows positive results — 6-K · Oct 31, 2025
- Sanofi Prices $3 Billion Bond Issuance — 6-K · Oct 28, 2025
- Sanofi Files 6-K with Mid-Year Financial Updates — 6-K · Oct 27, 2025
- Sanofi Files 6-K, Updates EU Rezurock Review — 6-K · Oct 24, 2025
- Sanofi Files 6-K Report for October 2025 — 6-K · Oct 24, 2025
- Sanofi's AlphaMedixTM Drug Meets Phase 2 Efficacy Endpoints — 6-K · Oct 15, 2025
- Sanofi Drug SAR446268 Gets FDA Fast Track Nod — 6-K · Sep 26, 2025
- Sanofi's Dupixent Gets EU Green Light for Urticaria — 6-K · Sep 22, 2025
- Sanofi's Tzield approved in China; Q3 sales rise 3.1% — 6-K · Sep 17, 2025
- Sanofi's amlitelimab succeeds in Phase 3 atopic dermatitis study — 6-K · Sep 4, 2025
- Sanofi's Wayrilz Approved in US for Immune Thrombocytopenia — 6-K · Sep 3, 2025
- Sanofi's Rilzabrutinib Gets EU Orphan Designation — 6-K · Aug 29, 2025
- Sanofi Completes Vigil Neuroscience Acquisition — 6-K · Aug 7, 2025
- Sanofi's Sarclisa Gets EU Approval for Multiple Myeloma — 6-K · Jul 31, 2025
- Sanofi Files 6-K Report for July 2025 — 6-K · Jul 31, 2025
- Sanofi 13F-HR Filing — 13F-HR · Jul 29, 2025
- Sanofi's SAR446597 Gets FDA Fast Track for Geographic Atrophy — 6-K · Jul 22, 2025
- Sanofi Files 6-K Report — 6-K · Jul 18, 2025
- Sanofi's Riliprubart Gets US Orphan Drug Nod — 6-K · Jul 2, 2025
- Sanofi's Dupixent Outperforms Xolair in CRS Study — 6-K · Jun 24, 2025
- Sanofi Prices €1.5 Billion Bond Issue — 6-K · Jun 18, 2025
- Sanofi Ramps Up Beyfortus Shipments Ahead of RSV Season — 6-K · Jun 17, 2025
- Sanofi's Rilzabrutinib gets US Orphan Drug status for sickle cell — 6-K · Jun 6, 2025
- Sanofi and Blueprint Medicines Announce Collaboration — 6-K · Jun 2, 2025
- Sanofi Completes DR-0201 Acquisition, Updates on Beyfortus — 6-K · May 30, 2025
- Sanofi to Acquire Vigil Neuroscience for $1.4B — 6-K · May 22, 2025
- Sanofi 13F-HR Filing — 13F-HR · May 6, 2025
- Sanofi Files 6-K on April 30th Annual Meeting — 6-K · May 5, 2025
- Sanofi Closes Opella Deal, Creates Consumer Health Leader — 6-K · Apr 30, 2025
- Sanofi Files 6-K Report for April 2025 — 6-K · Apr 24, 2025
- Sanofi's Dupixent Approved for Chronic Spontaneous Urticaria in US — 6-K · Apr 22, 2025
- Sanofi Respiratory Pipeline Advances with New Asthma Data, COPD Studies Planned — 6-K · Apr 16, 2025
- Sanofi's Tolebrutinib Shows MS Disability Benefit in Phase 3 — 6-K · Apr 10, 2025
- Sanofi's Rilzabrutinib Gets Orphan Drug Status for Rare Diseases — 6-K · Apr 4, 2025
- Sanofi's Dupixent Approved in Japan for COPD — 6-K · Apr 2, 2025
- Sanofi's Tolebrutinib Gets FDA Priority Review for MS — 6-K · Mar 26, 2025
- Sanofi to Acquire Dren Bio to Boost Immunology Pipeline — 6-K · Mar 20, 2025
- Sanofi's Dupixent Shows Promise in Bullous Pemphigoid Trial — 6-K · Mar 10, 2025
- Sanofi Prices EUR 1.5 Billion Bond Issue — 6-K · Mar 6, 2025
- Sanofi Presents New Duvakitug Data at ECCO 2025 — 6-K · Feb 28, 2025
- Sanofi's Dupixent Gets FDA Priority Review for Bullous Pemphigoid — 6-K · Feb 20, 2025